CDMOs offering Recombinant Protein Manufacturing with Antibody-Drug Conjugate (ADC) in United States
8 matching organizations
Recombinant Protein Manufacturing with Antibody-Drug Conjugate (ADC) in United States is a frequent shortlist pattern for sponsors evaluating CDMO partners with regional footprint. This page lists organizations that map to all three dimensions so you can move from broad taxonomy browsing to a geography-aware candidate set.
Profiles emphasize fit-first discovery: review scope, regulatory posture, and provenance on each listing rather than treating this page as a single ranked recommendation.
When you need additional filters (indications, claim status, or free-text search), continue to the main search experience and layer criteria on top of this starting point.
- AGC Biologics
Global CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
- Abzena
Fully integrated biologics and bioconjugates CDMO+CRO offering drug design, development, and GMP manufacturing for antibodies, ADCs, AOCs, RDCs, and vaccines from discovery through commercial scale.
- Avid Bioservices
Avid Bioservices is a U.S.-based mammalian cell culture CDMO providing integrated process development, analytical development, and CGMP biologics manufacturing from DNA to IND to commercial supply, with 30+ years of expertise and FDA-inspected facilities in California.
- BSP Pharmaceuticals
BSP Pharmaceuticals is a CDMO specializing in development and manufacturing of cytotoxic oncology drugs, ADCs, peptides, proteins, and lipid-based formulations from preclinical GLP through commercial supply.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- Samsung Biologics
Leading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
- Syngene International
Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- Wheeler Bio
Oklahoma-based CDMO specializing in antibody-based therapeutics from cell line development through cGMP drug substance and drug product manufacturing, featuring the ModularCMC™ platform for phase-appropriate development.
Markdown mirror: /explore/svc_recombinant_protein_mfg/mod_adc/us.md